KẾT QUẢ ĐIỀU TRỊ PHÙ HOÀNG ĐIỂM DO ĐÁI THÁO ĐƯỜNG BẰNG TIÊM BEVACIZUMAB NỘI NHÃN TẠI BỆNH VIỆN KIẾN AN

Abstract

Objective: To evaluate the treatment outcomes of intravitreal Bevacizumab for diabetic macular edema (DME) at Kien An Hospital. Methods: This prospective clinical intervention study included 29 eyes of 16 patients with DME, conducted from August 2024 to August 2025. Patients received three consecutive intravitreal Bevacizumab injections, each 4 weeks apart. Visual acuity, central macular thickness (OCT), and treatment-related complications were recorded. Results: The mean age was 64.5 ± 8.1 years, with equal gender distribution. Most patients had type 2 diabetes (93.8%), with a mean disease duration of 6.87 ± 3.64 years. The baseline means central macular thickness was394 ± 67 µm. Diffuse macular edema was predominant (51.7%), followed by cystoid type (27.6%). Sub-conjunctival hemorrhage occurred in 10.3% of treated eyes. No ocular adverse events or systemic complications related to the injections were observed. Conclusion: Intravitreal Bevacizumab for diabetic macular edema at Kien An Hospital demonstrates initial effectiveness and a safety profle with low rate of mild complications.